The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
The company has solid fundamentals for a short-term investment strategy.
Merck And Company accounts for 4.85 % of our USA Portfolio. A trade is currently open since 10/23/2019 with a purchase price of $ 81.71. Discover the other 19 stocks of the USA portfolio managed by the MarketScreener portfolio management team.
The group's activity appears highly profitable thanks to its outperforming net margins.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The stock is in a well-established, long-term rising trend above the technical support level at 79.73 USD
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Based on current prices, the company has particularly high valuation levels.